Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients
Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients
复制标题
DOI：
10.1007/s11060-018-2803-y
复制
发表时间：
2018-06-01
影响因子：
3.9
通讯作者：
Deltuva, Vytenis
中科院分区：
文献类型：
--
作者：
Bunevicius, Adomas;Radziunas, Andrius;Deltuva, Vytenis
超敏C反应蛋白（hsCRP）和白细胞介素-6（IL-6）可作为脑肿瘤患者的重要预后指标。我们研究了循环中IL-6和hsCRP浓度与胶质瘤和脑膜瘤患者出院结局和生存率的关系。163例（115例女性;中位年龄57岁）因脑膜瘤（n = 94）、高级别胶质瘤（n = 48）和低级别胶质瘤（n = 21）手术而入院的患者入组本前瞻性队列研究。在入院后24小时内采集血清样本。使用格拉斯哥结局量表（不良结局= 1 - 3分）评价出院结局。随访持续至2016年11月。分别有25%和35%的脑肿瘤患者存在IL-6（>= 2 pg/ml）和hsCRP（>= 1 mg/l）浓度升高。IL-6浓度升高与出院时的不良结局相关，调整了脑肿瘤组织学诊断、患者年龄和性别（OR 2.39，95%CI 0.97-5.91，p = 0.05）。hsCRP浓度升高与出院结局无关（p = 0.13）。在多变量考克斯回归分析中，调整了患者的年龄、性别、肿瘤切除程度和辅助治疗，IL-6浓度升高与高级别胶质瘤患者的死亡风险增加相关（OR 2.623; 95%CI 1.129-5.597; p = 0.01），而hsCRP浓度升高与脑膜瘤患者更高的死亡风险相关（OR 3.650; 95% CI 1.038-12.831; p = 0.04）。IL-6浓度升高与脑肿瘤患者更大的不良结局风险相关，与高级别胶质瘤患者更高的死亡率相关，而hsCRP浓度升高与脑膜瘤患者更高的死亡率相关。
High sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) can be important prognostic indicators of brain tumor patients. We investigated the association of circulating IL-6 and hsCRP concentrations with discharge outcomes and survival of glioma and meningioma patients. One-hundred and sixty-three (115 women; median age 57 years) patients admitted for meningioma (n = 94), high-grade glioma (n = 48) and low-grade glioma (n = 21) surgery were enrolled in this prospective cohort study. Serum samples were collected within 24 h of admission. Discharge outcome was evaluated using the Glasgow Outcome Scale (unfavorable outcome = score from 1 to 3). Follow-up continued until November, 2016. Elevated IL-6 (>= 2 pg/ml) and hsCRP (>= 1 mg/l) concentrations were present in 25 and 35% of brain tumor patients, respectively. Elevated IL-6 concentrations were associated with unfavorable outcome at hospital discharge, adjusting for brain tumor histological diagnosis, patient age and gender (OR 2.39, 95% CI 0.97-5.91, p = 0.05). Elevated hsCRP concentrations were not associated with discharge outcome (p = 0.13). In multivariate Cox regression analyses adjusted for patient age, gender, extent of tumor resection and adjuvant treatment, elevated IL-6 concentration was associated with greater mortality risk in high-grade glioma patients (OR 2.623; 95% CI 1.129-5.597; p = 0.01), while elevated hsCRP concentration was associated with greater mortality risk in meningioma patients (OR 3.650; 95% CI 1.038-12.831; p = 0.04). Elevated IL-6 concentration is associated with greater unfavorable outcome risk in brain tumor patients and with greater mortality in high-grade glioma patients, while elevated hsCRP concentration is associated with greater mortality in meningioma patients.